The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats.
Passive immunization with monoclonal antibodies (mAbs) against (+)-methamphetamine (METH) is being evaluated for the treatment of METH addiction. A human/mouse chimeric form of the murine anti-METH mAb7F9 has entered clinical trials. This study examined the effects of murine mAb7F9 on certain addict...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4350938?pdf=render |
| _version_ | 1819075718918701056 |
|---|---|
| author | Andrew C Harris Mark G LeSage David Shelley Jennifer L Perry Paul R Pentel S Michael Owens |
| author_facet | Andrew C Harris Mark G LeSage David Shelley Jennifer L Perry Paul R Pentel S Michael Owens |
| author_sort | Andrew C Harris |
| collection | DOAJ |
| description | Passive immunization with monoclonal antibodies (mAbs) against (+)-methamphetamine (METH) is being evaluated for the treatment of METH addiction. A human/mouse chimeric form of the murine anti-METH mAb7F9 has entered clinical trials. This study examined the effects of murine mAb7F9 on certain addiction-related behavioral effects of METH in rats as measured using intracranial self-stimulation (ICSS). Initial studies indicated that acute METH (0.1-0.56 mg/kg, s.c.) lowered the minimal (threshold) stimulation intensity that maintained ICSS. METH (0.3 mg/kg, s.c.) also blocked elevations in ICSS thresholds (anhedonia-like behavior) during spontaneous withdrawal from a chronic METH infusion (10 mg/kg/day x 7 days). In studies examining effects of i.v. pretreatment with mAb7F9 (at 30, 100, or 200 mg/kg), 200 mg/kg blocked the ability of an initial injection of METH (0.3 mg/kg, s.c.) to reduce baseline ICSS thresholds, but was less capable of attenuating the effect of subsequent daily injections of METH. MAb7F9 (200 mg/kg) also produced a small but significant reduction in the ability of METH (0.3 mg/kg, s.c.) to reverse METH withdrawal-induced elevations in ICSS thresholds. These studies demonstrate that mAb7F9 can partially attenuate some addiction-related effects of acute METH in an ICSS model, and provide some support for the therapeutic potential of mAb7F9 for the treatment of METH addiction. |
| first_indexed | 2024-12-21T18:29:52Z |
| format | Article |
| id | doaj.art-dc8054b2511442b08a2ff0d28b49e3cb |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T18:29:52Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-dc8054b2511442b08a2ff0d28b49e3cb2022-12-21T18:54:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01103e011878710.1371/journal.pone.0118787The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats.Andrew C HarrisMark G LeSageDavid ShelleyJennifer L PerryPaul R PentelS Michael OwensPassive immunization with monoclonal antibodies (mAbs) against (+)-methamphetamine (METH) is being evaluated for the treatment of METH addiction. A human/mouse chimeric form of the murine anti-METH mAb7F9 has entered clinical trials. This study examined the effects of murine mAb7F9 on certain addiction-related behavioral effects of METH in rats as measured using intracranial self-stimulation (ICSS). Initial studies indicated that acute METH (0.1-0.56 mg/kg, s.c.) lowered the minimal (threshold) stimulation intensity that maintained ICSS. METH (0.3 mg/kg, s.c.) also blocked elevations in ICSS thresholds (anhedonia-like behavior) during spontaneous withdrawal from a chronic METH infusion (10 mg/kg/day x 7 days). In studies examining effects of i.v. pretreatment with mAb7F9 (at 30, 100, or 200 mg/kg), 200 mg/kg blocked the ability of an initial injection of METH (0.3 mg/kg, s.c.) to reduce baseline ICSS thresholds, but was less capable of attenuating the effect of subsequent daily injections of METH. MAb7F9 (200 mg/kg) also produced a small but significant reduction in the ability of METH (0.3 mg/kg, s.c.) to reverse METH withdrawal-induced elevations in ICSS thresholds. These studies demonstrate that mAb7F9 can partially attenuate some addiction-related effects of acute METH in an ICSS model, and provide some support for the therapeutic potential of mAb7F9 for the treatment of METH addiction.http://europepmc.org/articles/PMC4350938?pdf=render |
| spellingShingle | Andrew C Harris Mark G LeSage David Shelley Jennifer L Perry Paul R Pentel S Michael Owens The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats. PLoS ONE |
| title | The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats. |
| title_full | The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats. |
| title_fullStr | The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats. |
| title_full_unstemmed | The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats. |
| title_short | The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats. |
| title_sort | anti methamphetamine monoclonal antibody mab7f9 attenuates acute methamphetamine effects on intracranial self stimulation in rats |
| url | http://europepmc.org/articles/PMC4350938?pdf=render |
| work_keys_str_mv | AT andrewcharris theantimethamphetaminemonoclonalantibodymab7f9attenuatesacutemethamphetamineeffectsonintracranialselfstimulationinrats AT markglesage theantimethamphetaminemonoclonalantibodymab7f9attenuatesacutemethamphetamineeffectsonintracranialselfstimulationinrats AT davidshelley theantimethamphetaminemonoclonalantibodymab7f9attenuatesacutemethamphetamineeffectsonintracranialselfstimulationinrats AT jenniferlperry theantimethamphetaminemonoclonalantibodymab7f9attenuatesacutemethamphetamineeffectsonintracranialselfstimulationinrats AT paulrpentel theantimethamphetaminemonoclonalantibodymab7f9attenuatesacutemethamphetamineeffectsonintracranialselfstimulationinrats AT smichaelowens theantimethamphetaminemonoclonalantibodymab7f9attenuatesacutemethamphetamineeffectsonintracranialselfstimulationinrats AT andrewcharris antimethamphetaminemonoclonalantibodymab7f9attenuatesacutemethamphetamineeffectsonintracranialselfstimulationinrats AT markglesage antimethamphetaminemonoclonalantibodymab7f9attenuatesacutemethamphetamineeffectsonintracranialselfstimulationinrats AT davidshelley antimethamphetaminemonoclonalantibodymab7f9attenuatesacutemethamphetamineeffectsonintracranialselfstimulationinrats AT jenniferlperry antimethamphetaminemonoclonalantibodymab7f9attenuatesacutemethamphetamineeffectsonintracranialselfstimulationinrats AT paulrpentel antimethamphetaminemonoclonalantibodymab7f9attenuatesacutemethamphetamineeffectsonintracranialselfstimulationinrats AT smichaelowens antimethamphetaminemonoclonalantibodymab7f9attenuatesacutemethamphetamineeffectsonintracranialselfstimulationinrats |